THE WOODLANDS, Texas, May 17 (UPI) -- U.S. firm Opexa Therapeutics said it has finished enrolling patients in a phase 2b study of its T-cell vaccine Tovaxin for multiple sclerosis.
The company said it has recruited 150 patients with clinically isolated syndrome or relapsing/remitting forms of MS.
The patients will receive treatment for 52 weeks, with investigators analyzing data on the first 75 subjects to reach six months evaluability later this year.
"With this milestone achieved, we now look forward to reporting a descriptive analysis in the fourth quarter of 2007 and the full data results in the second half of 2008," said Opexa president and chief executive officer David McWilliams. "I am convinced that the ability to rapidly enroll this study across 35 U.S. centers reflects the high level of interest by multiple sclerosis patients in new safe and effective treatments."
Opexa said that studies of the T-cell vaccine show that vaccinating MS patients with peripheral, blood-derived, autologous, myelin-peptide selected T-cells appears to elicit the appropriate immune response.
